Compare PLSE & AUPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PLSE | AUPH |
|---|---|---|
| Founded | 2014 | 1993 |
| Country | United States | Canada |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.5B | 1.9B |
| IPO Year | 2015 | 2014 |
| Metric | PLSE | AUPH |
|---|---|---|
| Price | $19.15 | $15.72 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 1 | 4 |
| Target Price | ★ $22.00 | $17.25 |
| AVG Volume (30 Days) | 235.0K | ★ 1.1M |
| Earning Date | 05-07-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 5075.00 |
| EPS | N/A | ★ 2.07 |
| Revenue | N/A | ★ $283,055,000.00 |
| Revenue This Year | $840.00 | $16.53 |
| Revenue Next Year | $287.54 | $16.24 |
| P/E Ratio | ★ N/A | $7.73 |
| Revenue Growth | N/A | ★ 20.38 |
| 52 Week Low | $12.56 | $6.83 |
| 52 Week High | $26.30 | $16.54 |
| Indicator | PLSE | AUPH |
|---|---|---|
| Relative Strength Index (RSI) | 43.99 | 63.32 |
| Support Level | $13.75 | $14.56 |
| Resistance Level | $20.40 | $16.28 |
| Average True Range (ATR) | 1.55 | 0.56 |
| MACD | -0.13 | 0.20 |
| Stochastic Oscillator | 18.85 | 79.04 |
Pulse Biosciences Inc is a novel bioelectric medicine company committed to health innovation using its patented Nano-Pulse Stimulation technology, a revolutionary energy modality that delivers nanosecond-duration pulses of electrical energy, each less than a millionth of a second long, to non-thermally clear targeted cells while sparing adjacent noncellular tissue. NPS technology, also referred to as Nanosecond Pulsed-Field Ablation or nsPFA technology when used to ablate cellular tissue, can be used to treat a variety of medical conditions for which an optimal solution remains unfulfilled.
Aurinia Pharmaceuticals Inc is a biopharmaceutical company focused on delivering therapies to people living with autoimmune diseases with high unmet medical needs. The company developed LUPKYNIS (voclosporin), the first FDA-approved oral therapy for the treatment of adult patients with active lupus nephritis. It is also developing aritinercept, a dual inhibitor of B cell activating factor (BAFF) and a proliferation-inducing ligand (APRIL), for the potential treatment of autoimmune diseases.